Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Triple-negative breast cancer (TNBC) is a subtype of human breast cancer with one of the
worst prognoses, with no targeted therapeutic strategies currently available. Regulated cell …

Background Addition of immune checkpoint inhibitors to neoadjuvant chemotherapy (NACT)
is a promising strategy in early breast cancer, but the optimal duration of therapy is currently …

CD8+ tumor-infiltrating lymphocytes with a tissue-resident memory T (T RM) cell phenotype
are associated with favorable prognosis in patients with triple-negative breast cancer …

Immunotherapy, particularly agents targeting the immunoregulatory PD-1/PD-L1 axis,
harnesses the power of the immune system to treat cancer, with unique potential for a …

Triple-negative breast cancer (TNBC) is a highly heterogeneous disease defined by the
absence of estrogen receptor (ER) and progesterone receptor (PR) expression, and human …

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer,
which is characterized by the absence of estrogen receptor (ER) and progesterone receptor …

The impact of single-agent antibodies against programmed death-ligand 1 (PD-L1) as
maintenance therapy is unknown in patients with metastatic breast cancer. The SAFIR02 …

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly
improved survival in several cancer settings. A subgroup of women with breast cancer (BC) …

Simple Summary For decades, countless efforts have been devoted to developing targeted
drugs to improve the prognosis of triple-negative breast cancer (TNBC). Among the novel …